Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ALMS
ALUMIS INC.
NASDAQ
$22.38
▼ DOWN 3.58% (-0.83)

KEY STATISTICS

Market Cap$2.76 B
52w High$31.35
52w Low$3.76
Dividend Yield—
Frequency—
P/E-5.71
Volume655.02K
Shares Out.123.43M

COMPANY

LEADERSHIP

Martin Babler
CHIEF EXECUTIVE
Martin Babler

COMPENSATION 2026

Salary$680,830
Stock Awards$0
Incentive Plan Pay$524,239
All Other Comp.$0
Total$5,948,289

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 28, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
237

PRICE TARGET

Target High$51.00
Target Low$25.00
Target Median$39.50
Target Consensus$39.17

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$1.90M
NOV
12
THU

PRICE

$22.38 ▼ DOWN 3.58% (−$0.83)
$22.40$22.60$22.809:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM22.38

About Alumis Inc.

https://www.alumis.com ↗

Alumis Inc., a clinical-stage biopharmaceutical company based in South San Francisco, develops TYK2 inhibitors like ESK-001 and A-005 for autoimmune, neuroinflammatory, and neurodegenerative diseases.

INDUSTRY

Biotechnology

A PRODUCT ALUMIS INC. IS KNOWN FOR

Envudeucitinib
Envudeucitinib

Alumis Inc.'s leading late-stage clinical candidate is a highly selective oral allosteric TYK2 inhibitor being developed for moderate-to-severe plaque psoriasis and systemic lupus erythematosus.

COMPETITORS

COMPETITOR
BMY COMPARE
JNJ COMPARE
PFE COMPARE
TAK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Collaboration Revenue$2.07M $1.93M ▼$1.74M ▼$1.66M ▼
License$17.39M $0 ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
129
LISTED HERE
25
RANKED BY POSITION SIZE
VTI
0.00% · 3.2M
IWM
0.06% · 2.0M
XPH
1.64% · 415.7K
SCHA
0.04% · 405.4K
TMSL
0.16% · 203.5K
FYC
0.32% · 198.7K
FESM
0.04% · 126.7K
USVM
0.16% · 126.5K
PRFZ
0.08% · 99.9K
NUSC
0.11% · 72.1K
XRS2.F
0.06% · 72.0K
RSSL
0.06% · 37.6K
GSSC
0.06% · 26.2K
BBSC
0.06% · 20.9K
BBC
0.58% · 13.0K
PILL
1.10% · 11.7K
BIB
0.10% · 4.4K
STXK
0.10% · 4.0K
RFLR
0.07% · 2.9K
RTWP.L
0.03% · 2.7K
BKSE
0.06% · 2.6K
DFAU
0.00% · 612
USFMDN.MX
0.00% · 341
RESM
0.09% · 249
AVSU
0.00% · 60

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.60%
HOLDERS
255
TOP 12 OF 255 · RANKED BY POSITION SIZE
Ayurmaya Capital Management Company, LP
15.1M sh · $426.03M
Blackrock, Inc.
8.2M sh · $231.26M
Deep Track Capital, LP
6.8M sh · $149.2M
Fmr LLC
6.8M sh · $190.48M
Samsara Biocapital, LLC
6.3M sh · $139.79M
Foresite Capital Management V, LLC
5.9M sh · $129.91M
Price T Rowe Associates Inc /Md/
5.2M sh · $146.32M
Venbio Partners LLC
4.6M sh · $18.43M
Foresite Capital Management Vi LLC
4.2M sh · $119.53M
Vanguard Group Inc
4.1M sh · $40.05M
Cormorant Asset Management, LP
3.9M sh · $87M
Nextech Invest, Ltd.
3.5M sh · $78.01M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Schroer John R.
Sale · 3.3K shares
2026-08-03
★
OFFICER: CHIEF LEGAL OFFICER
Pangali Sanam
Sale · 1.4K shares
2026-08-03
★
OFFICER: CHIEF BUSINESS & STRATEGY OFCR
Hardiman Roy C.
Sale · 2.7K shares
2026-08-03
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Goldstein David M
Sale · 2.6K shares
2026-08-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 2
OUTPERFORM 2
NEUTRAL 1
7 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. NEUTRAL Chardan Capital BUY Guggenheim BUY Wells Fargo OVERWEIGHT Oppenheimer OUTPERFORM Morgan Stanley OVERWEIGHT Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
ETON$59.78COMPARE
OMER$18.61COMPARE
LXRX$2.29COMPARE
OCGN$1.32COMPARE
FULC$3.85COMPARE
BCYC$4.20COMPARE
NMRA$1.39COMPARE
ADCT$1.14COMPARE